These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38190779)

  • 1. SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease.
    Yang C; Xiao C; Zhai X; Liu J; Yu M
    J Diabetes Complications; 2024 Feb; 38(2):108652. PubMed ID: 38190779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats.
    Kimura Y; Kuno A; Tanno M; Sato T; Ohno K; Shibata S; Nakata K; Sugawara H; Abe K; Igaki Y; Yano T; Miki T; Miura T
    J Diabetes Investig; 2019 Jul; 10(4):933-946. PubMed ID: 30663266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect.
    Corremans R; Vervaet BA; Dams G; D'Haese PC; Verhulst A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
    Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
    Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
    Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
    BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
    Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
    Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
    Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
    Lanthier L; Huard G; Plourde MÉ; Cauchon M
    Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
    Heerspink HJL; Perco P; Mulder S; Leierer J; Hansen MK; Heinzel A; Mayer G
    Diabetologia; 2019 Jul; 62(7):1154-1166. PubMed ID: 31001673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
    Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
    Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
    Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
    J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
    Kabil SL; Mahmoud NM
    Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
    Li J; Liu H; Takagi S; Nitta K; Kitada M; Srivastava SP; Takagaki Y; Kanasaki K; Koya D
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32134397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.